Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH -- Ignore unavailable to you. Want to Upgrade?

To: Kevin McKenzie who wrote (425)	12/18/1998 1:57:00 AM
From: John Miz	Read Replies (1) \| Respond to of 1084

Here's something that's really old. (1996?) But it sort of traces the history of Aastrom Biosciences. PREPARED STATEMENT BY MICHAEL KANTOR SECRETARY OF COMMERCE BEFORE THE SUBCOMMITTEE ON COMMERCE, JUSTICE, STATE AND JUDICIARY COMMITTEE ON APPROPRIATIONS UNITED STATES HOUSE OF REPRESENTATIVES MAY 9, 1996 Let me share just one of the many success stories that these ATP grants have made possible. In 1992, Aastrom Biosciences of Ann Arbor, Michigan, had 15 employees and a vision that human blood cells could be grown in an artificial environment. If this were possible, clinical research into many types of diseases -- cancer, genetic blood diseases, AIDS -- would be greatly facilitated. But Aastrom Biosciences needed to increase their capacity greatly, in order to make the blood cell production process feasible. With the help of their ATP grant, Aastrom Biosciences has developed a prototype clinical process, and their blood cell bioreactor has attracted $20 million in private investment funding, clearly making it a viable commercial product. The company now employs 45 people. End Of Statement by Secretary of Commerce Michael Kantor. Well slowly, but surely, Aastrom's Replicell system is finally going to market. It will, hopefully, be an exciting company to follow over the next couple of years. John